INUS
Straddle Chart

Markets / Mutual funds / Sectoral / Thematic

Mutual fundsSIF

HDFC Pharma and Healthcare Fund - Direct Plan - Growth

NAVs of 8 Nov 2026

HDFC Mutual Fund · Equity fund · Direct plan · Growth

Sectoral / ThematicDirect · GrowthRisk: Very High
NAV · 6 Nov 2026
₹22.8150 ▲ 0.89%
HDFC Mutual Fund
Fund size₹3,128 crJuly - September 2026
1-month range₹20.66 – 22.82
1 year+28.23%rank 3 of 204
Expense ratio1.02%direct plan, a year
5 years–a year

What the fund does

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.

BenchmarkBSE Healthcare Index (TRI)
Fund houseHDFC Mutual Fund
Fund managersFM 1 - Mr. Nikhil MathurFM 2 - Mr. Gopal AgrawalFM 3 - Mr. Bhagyesh Kagalkar

NAV history

212223 2026-08-122026-08-252026-09-072026-09-212026-10-052026-10-162026-10-30

Returns

1 week
+3.93%avg 5.2%
1 month
+4.10%avg 3.0%
3 months
+2.82%avg -1.6%
6 months
+15.71%avg 3.7%
This year
+28.87%avg 4.5%
1 year
+28.23%avg 5.5% · #3/204
3 years (a year)
+31.72%avg 15.3% · #3/127

Bars: this plan; the thin mark is the Sectoral / Thematic average (direct plans, growth option). Over a year: yearly averages (CAGR). Past returns do not guarantee future returns. Information only, not investment advice.

Monthly returns (%)

YearJanFebMarAprMayJunJulAugSepOctNovDec
2024+2.0
2025-5.3-8.2+9.4+0.4+1.6+2.7+6.2-3.4-1.6+3.4+1.5-1.7
2026-4.2+7.9-4.4+7.5+5.9+5.8+3.4+3.8-3.0+0.0+3.9

Each month's change in NAV (the current month to the latest NAV).

What if you had invested?

Worked out from this plan's actual NAVs. SIP: invested on the first NAV of each month. Taxes and exit loads are not included. Past returns do not guarantee future returns. Information only, not investment advice.

Portfolio as on 30 Sept 2026

Stocks held3840 lines in all
Top 10 stocks47.8%of the fund
Short positions-1.4%sold through derivatives
Net equity95.3%long stocks and derivatives minus shorts

Where the money is

Equity 96.8%Cash & others 3.2%Short -1.4%

Sectors (stocks held)

Pharmaceuticals & Biotechnology
71.3%
Healthcare Services
22.1%
Healthcare Equipment & Supplies
2.4%
Retailing
1.0%

Stocks held 38

HoldingSector / type% of fund
Divis Laboratories Ltd.
INE361B01024		Pharmaceuticals & Biotechnology9.39%
Sun Pharmaceutical Industries Ltd.
INE044A01036		Pharmaceuticals & Biotechnology8.28%
Alkem Laboratories Ltd.
INE540L01014		Pharmaceuticals & Biotechnology4.64%
Cipla Ltd.
INE059A01026		Pharmaceuticals & Biotechnology4.15%
Apollo Hospitals Enterprise Ltd.
INE437A01024		Healthcare Services3.69%
Torrent Pharmaceuticals Ltd.
INE685A01028		Pharmaceuticals & Biotechnology3.65%
Max Healthcare Institute Limited
INE027H01010		Healthcare Services3.61%
Aster DM Quality Care Limited
INE914M01019		Healthcare Services3.56%
Lupin Ltd.
INE326A01037		Pharmaceuticals & Biotechnology3.55%
Neuland Laboratories Limited
INE794A01010		Pharmaceuticals & Biotechnology3.24%
Shilpa Medicare Ltd
INE790G01031		Pharmaceuticals & Biotechnology3.23%
Dr Reddys Laboratories Ltd.
INE089A01031		Pharmaceuticals & Biotechnology3.19%
Acutaas Chemicals Limited
INE00FF01025		Pharmaceuticals & Biotechnology3.18%
Anthem Biosciences Limited
INE0CZ201020		Pharmaceuticals & Biotechnology3.17%
Ipca Laboratories Ltd.
INE571A01038		Pharmaceuticals & Biotechnology2.98%
Global Health Limited
INE474Q01031		Healthcare Services2.72%
Rubicon Research Limited
INE506V01022		Pharmaceuticals & Biotechnology2.52%
Krishna Institute Of Medical Sciences Limited
INE967H01025		Healthcare Services2.10%
Glenmark Pharmaceuticals Ltd.
INE935A01035		Pharmaceuticals & Biotechnology2.09%
Molbio Diagnostics Limited
INE869T01028		Healthcare Equipment & Supplies2.01%
Vijaya Diagnostic Centre Limited
INE043W01024		Healthcare Services2.00%
Zydus Lifesciences Limited
INE010B01027		Pharmaceuticals & Biotechnology1.82%
Gland Pharma Ltd.
INE068V01023		Pharmaceuticals & Biotechnology1.78%
Wockhardt Ltd.
INE049B01025		Pharmaceuticals & Biotechnology1.71%
Jupiter Life Line Hospitals Limited
INE682M01020		Healthcare Services1.68%
Metropolis Healthcare Ltd.
INE112L01020		Healthcare Services1.67%
Sai Life Sciences Limited
INE570L01029		Pharmaceuticals & Biotechnology1.58%
Biocon Ltd.
INE376G01013		Pharmaceuticals & Biotechnology1.47%
SYMBIOTEC PHARMALAB LIMITED
INE899I01028		Pharmaceuticals & Biotechnology1.36%
Thyrocare Technologies Ltd.
INE594H01019		Healthcare Services1.10%
CORONA REMEDIES LIMITED
INE02ZQ01018		Pharmaceuticals & Biotechnology1.04%
Entero Healthcare Solutions Limited
INE010601016		Retailing1.01%
Jubilant Pharmova Limited
INE700A01033		Pharmaceuticals & Biotechnology0.93%
Eris Lifesciences Ltd
INE406M01024		Pharmaceuticals & Biotechnology0.92%
Novartis India Ltd.
INE234A01025		Pharmaceuticals & Biotechnology0.55%
BAJAJ HEALTHCARE LIMITED
INE411U01027		Pharmaceuticals & Biotechnology0.53%
Laxmi Dental Limited
INE0WO601020		Healthcare Equipment & Supplies0.35%
Cohance Lifesciences Limited
INE03QK01018		Pharmaceuticals & Biotechnology0.32%

Short positions 1

HoldingSector / type% of fund
Net Current Assets–-1.44%

Debt, money market and cash 1

HoldingSector / type% of fund
TREPS - Tri-party Repo–4.67%

From the fund house's monthly portfolio (), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.

Risk

Volatility13.7%yearly, from daily NAVs
Worst fall-14.67%3 Jan 2025 → 28 Feb 2025
RiskometerVery HighVery High

Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 31 Oct 2023).

Where it can invest (limits from the scheme document)

Equity and Equity related instruments of Pharma and healthcare companies/entities#
80–100%
Equity and equity related instruments of companies/entities other than above
0–20%
Units of InvITs
0–10%
Money market instruments, Other liquid instruments and Units of Mutual Fund^^
0–20%
Gold and Silver instruments
0–20%

The ranges the fund is allowed to hold, not what it holds today.

Fund details

Fund size (average AUM, July - September 2026)₹3,128 cr across all plans · this plan ₹1,133 cr
Fund houseHDFC Mutual Fund
CategoryEquity · Sectoral / Thematic
PlanDirect
OptionGrowth
Expense ratio (TER)Direct 1.02% · Regular 2.11% (4 Nov 2026)
Exit loadIn respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment.
Minimum investment₹100 · additional ₹100
Scheme code (AMFI)152082
ISININF179KC1HO1
NAV date6 Nov 2026

Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.

Other plans of this fund

PlanNAV1 year
Direct · IDCW₹22.8150+28.23%
Regular · Growth₹21.9970+26.81%
Regular · IDCW₹21.9970+26.81%

Top Sectoral / Thematic funds (direct plans)

Fund1 year3 years (a year)
Nippon India Taiwan Equity Fund+39.55%+42.38%
HDFC Defence Fund+20.78%+35.14%
HDFC Pharma and Healthcare Fund+28.23%+31.72%
SBI HEALTHCARE OPPORTUNITIES FUND+22.32%+25.68%
HDFC Transportation and Logistics Fund+9.94%+25.29%
Mirae Asset Healthcare Fund+24.35%+25.21%
UTI - Healthcare Fund+18.81%+24.71%
ICICI PRUDENTIAL TRANSPORTATION AND LOGISTICS FUND+11.93%+23.21%

All Sectoral / Thematic funds ranked › · Compare with others ›

← All mutual funds

Information only, not investment advice.

What is the NAV of HDFC Pharma and Healthcare Fund - Direct Plan - Growth today?

₹22.8150 as of 6 Nov 2026, from AMFI's official NAV data.

What are the returns of HDFC Pharma and Healthcare Fund - Direct Plan - Growth?

1 year: 28.23%, 3 years: 31.72% a year

How does HDFC Pharma and Healthcare Fund rank in its category?

3 of 204 Sectoral / Thematic funds (direct plans, growth option) by 1-year return.

What is the difference between direct and regular plans?

Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.